Cargando…

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan

INTRODUCTION: This study aimed to clarify the efficacy and safety of omidenepag isopropyl (OMDI) in a retrospective, real-world, multicenter setting. METHODS: A retrospective medical chart review of patients with glaucoma and ocular hypertension receiving OMDI from November 2018 to November 2019 wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miki, Atsuya, Miyamoto, Etsuyo, Ishida, Naruhiro, Shii, Daisuke, Hori, Kiyotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056475/ https://www.ncbi.nlm.nih.gov/pubmed/35287233 http://dx.doi.org/10.1007/s12325-022-02069-6

Ejemplares similares

Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori, Naka, et al.
Publicado: (2021)

Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
por: Olander, Kenneth W., et al.
Publicado: (2021)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2020)

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
por: Nakazawa, Toru, et al.
Publicado: (2022)

Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension
por: Matsuo, Masato, et al.
Publicado: (2022)

Measurements of the nucleon structure function in the range 0.002 $<$ x $<$ 0.17 and 0.2 $<$ Q$^{2}$ $<$ 8 GeV$^{2}$ in deuterium, carbon and calcium
por: Arneodo, M, et al.
Publicado: (1989)

Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report
por: Bae, Byung-Jin, et al.
Publicado: (2023)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung, Derrick S, et al.
Publicado: (2014)

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
por: Singh, Inder P., et al.
Publicado: (2020)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl
por: Oogi, Satomi, et al.
Publicado: (2020)

Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study
por: Panarelli, Joseph F., et al.
Publicado: (2023)

A comparison of continuous infusion and intermittent bolus administration of 0.1% ropivacaine with 0.0002% fentanyl for epidural labor analgesia
por: Patkar, Chinmayi Surendra, et al.
Publicado: (2015)

Genome Sequence of Pasteurella multocida Razi 0002 of Avian Origin
por: Sprague, Lisa D., et al.
Publicado: (2017)

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
por: Aihara, Makoto, et al.
Publicado: (2019)

Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells
por: Suzuki, Soma, et al.
Publicado: (2022)

A Reference Proteomic Database of Lactobacillus plantarum CMCC-P0002
por: Zhu, Li, et al.
Publicado: (2011)

Improved Crystallinity of Annealed 0002 AlN Films on Sapphire Substrate
por: Bersch, Bruno Comis, et al.
Publicado: (2023)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Study on the growth of Al-doped ZnO thin films with (112̄0) and (0002) preferential orientations and their thermoelectric characteristics
por: Luo, Jing-Ting, et al.
Publicado: (2018)

Effect of Current Density on the Corrosion Resistance and Photocatalytic Properties of Cu-Ni-Zn(0.96)Ni(0.02)Cu(0.02)O Nanocomposite Coatings
por: Tan, Haifeng, et al.
Publicado: (2023)

Cloning, expression and characterization of a chitinase from Paenibacillus chitinolyticus strain UMBR 0002
por: Liu, Cong, et al.
Publicado: (2020)

Comptia Cloud+ study guide exam CV0-002
por: Montgomery, Todd, et al.
Publicado: (2018)

Biofilm reduction potential of 0.02% polyhexanide irrigation solution in several types of urethral catheters
por: Brill, Florian H. H., et al.
Publicado: (2021)

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
por: Esaki, Yoshihiko, et al.
Publicado: (2020)

Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells
por: Kim, Jeong Yeub, et al.
Publicado: (2022)

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections
por: Kanda, Yoshiko, et al.
Publicado: (2012)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Effect of 0.02% and 0.01% atropine on astigmatism: a two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2022)

CompTIA cloud+: certification study guide (exam CV0-002)
por: Wilson, Scott, et al.
Publicado: (2018)

CompTIA cloud+ certification practice exams (Exam CV0-002)
por: Lachance, Daniel
Publicado: (2018)

CompTIA CySa+ study guide exam CS0-002
por: Chapple, Mike, et al.
Publicado: (2020)

Decolonization potential of 0.02% polyhexanide irrigation solution in urethral catheters under practice-like in vitro conditions
por: Brill, Florian H. H., et al.
Publicado: (2018)

A New MiRNA MiRm0002 in Eggplant Participates in the Regulation of Defense Responses to Verticillium Wilt
por: Zhu, Wenjiao, et al.
Publicado: (2021)

Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2023)

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
por: Yamamoto, Yasuko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_94tr29e3o133veqq0enetvd8nq